Proteinuria treatment may not be readily available. However, addressing proteinuria often involves pharmaceutical companies that develop medications to manage underlying conditions causing protein leakage in the urine, such as kidney diseases, diabetes, or autoimmune disorders. It's important to note that the pharmaceutical landscape evolves, and new players may emerge.
AstraZeneca (UK) Announced positive Phase 3 trial results for Farxiga® (dapagliflozin) in July 2023, demonstrating its efficacy in reducing proteinuria in patients with chronic kidney disease. This established medication may offer a new indication for managing proteinuria.
Alnylam Pharmaceuticals (US) Received Breakthrough Therapy Designation from the FDA for vutrisiran in September 2023 for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a condition associated with proteinuria. This potential therapy aims to address a specific cause of proteinuria with a novel approach.
Khit Therapeutics (US) Developed KTX-01, a novel oral therapy currently in Phase 2 clinical trials, targeting a key pathway involved in proteinuria associated with focal segmental glomerulosclerosis (FSGS). This potential medication offers hope for a targeted treatment for a specific type of proteinuria.
Reata Pharmaceuticals Expanded its late-stage clinical development program for bardoxolone methyl ester (bardoxolone) in September 2023, with studies evaluating its efficacy in patients with diabetic kidney disease and chronic kidney disease associated with chronic heart failure. Bardoxolone may offer a multi-targeted approach for managing proteinuria and associated complications.
List of Proteinuria Treatment Key Companies in the Market
Proteinuria Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)